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Abstract 
T-cell receptor (TCR) triggering by an anti-CD3 antibody or phytohemagglutinin (PHA) as well as the treatment with phorbol 
myristate acetate (PMA), a direct activator of protein kinase C (PKC), induces activation of Ras in T-lymphocytes (Downward, J. et al. 
(1990) Nature 364, 719-723). In this paper, we studied the role of Ras in the process of TCR-mediated T-cell activation using a human 
lymphomic Jurkat cell line. The stimulatory effect of TCR cross-linking on Ras activation was inhibited by herbimycin A, a specific 
inhibitor of protein tyrosine kinases (PTKs), whereas PMA-induced Ras activation was not affected. On the other hand, calphostin C, a 
specific inhibitor of PKC, blocked not only PMA-induced, but also TCR-mediated formation of Ras • GTP. Furthermore, down-regulation 
of PMA-sensitive PKC severely impaired the activation of Ras in response to TCR-stimulation. Tyrosine-phosphorylation and 
translocation to the particulate fraction of phospholipase C-71 (PLC-3~ 1) were observed upon T-cell activation. Subcellular localization of 
PKC was also changed when the cells were stimulated with an anti-CD3 antibody or PMA. While TCR-stimulated translocation f PKC 
was observed only transiently, PMA-induced translocation of PKC was more sustained. These results suggest hat the activation of 
PLC-71 by PTK and subsequent activation of PKC are important for TCR-mediated Ras activation in Jurkat cells. An activated form of 
Ras enhanced the activation of interleukin 2 (IL-2) promoter by TCR stimulation or PMA treatment, although the activated Ras by itself 
was insufficient for IL-2 promoter activation. On the other hand, a dominant-inhibitory Ras diminished almost completely the activation 
of IL-2 promoter induced by PMA plus calcium ionophore, indicating that Ras is essential for transduction of T-cell activation signals. 
Cholera toxin (CTX), which directly activates Gs a, is shown to inhibit the activation of IL-2 promoter, TCR-mediated Ras activation, 
tyrosine phosphorylation a d translocation f cellular proteins including ZAP-70, PLC-71, and PKC. An activated G S a mutant as well as 
dibutylyl cAMP (dBcAMP) also showed similar inhibitory effects. 
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1. Introduction 
Ras protein is a member of the low-molecular-weight 
GTP-binding proteins regulating proliferation and differen- 
tiation in various types of cells (see Refs. [1-3] for re- 
views). The activity of Ras is regulated by signals sequen- 
tially transmitted through receptors, tyrosine kinases, adap- 
tor proteins, and guanine nucleotide xchange proteins (see 
Ref. [4] for a review). Guanine nucleotide xchange pro- 
teins stimulate formation of the active GTP-bound form of 
Ras, which interacts with downstream target molecules, for 
example, Raf- l  and B-Raf (see Ref. [5] for a review). 
Activation of T-lymphocytes i triggered by binding of 
foreign antigens to the T-cell receptor (TCR) complex 
consisting of a- and t-chains, CD3-y-, & and e-chains, 
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and a homodimer of ~-chains. Cellular protein tyrosine 
kinases (PTKs) such as Lck, Fyn, and ZAP-70 play critical 
roles in the TCR-mediated signaling systems. Stimulation 
of TCR also induces activation of phospholipase C-yl 
(PLC-yl) and protein kinase C (PKC). Finally, T-cell 
activation signals induce expression of several lymphokine 
genes including interleukin 2 (IL-2), IL-4, and y-inter- 
feron, and stimulate the proliferation of T-cells (see Refs. 
[6-8] for reviews). It has been shown that T-cell-activating 
antibodies or phorbol myristate acetate (PMA), a direct 
activator of PKC, stimulate the formation of Ras • GTP [9], 
suggesting a pivotal role of Ras in T-cell activation signal- 
ing [2]. 
In TCR-mediated signaling systems, cAMP-elevating 
agents inhibit several events initiated by TCR triggering, 
such as inositol 1,4,5-tris-phosphate (IP 3) production, ac- 
cumulation of cytoplasmic free calcium, and IL-2 produc- 
tion [10-12]. However, the modulation of lymphokine 
gene expression by cAMP occurs in different manners 
among different subsets of T-cells; cAMP inhibits the 
expression of IL-2 that is mainly produced by type 1 
helper T-cells, whereas, in type 2 helper T-cells, IL-5 
expression is enhanced and IL-4 promoter is not modified 
by cAMP signal [13-16]. 
In this study, we investigated the mechanism of activa- 
tion of Ras upon TCR cross-linking as well as the role of 
Ras in TCR-and PKC-mediated IL-2 gene expression 
using human T-cell line Jurkat. It was demonstrated that 
the stimulation of TCR and PKC induced Ras activation, 
and PKC was found to be critical for TCR-mediated Ras 
activation. Although expression of a mutationally activated 
Ras alone was not sufficient to stimulate the expression of 
IL-2 promoter, it enhanced the induction of IL-2 promoter 
in response to phytohemagglutinin (PHA), A23187, PMA, 
and their combination. When a dominant-inhibitory Ras 
was expressed, TCR- and PKC-mediated activation of IL-2 
promoter was dramatically inhibited, suggesting that Ras is 
essential for stimulation of IL-2 expression. We also ana- 
lyzed the effect of cholera toxin (CTX) and dibutylyl 
cAMP (dBcAMP) on TCR-mediated signals, and revealed 
that these reagents blocked the activation of IL-2 promoter, 
TCR-mediated Ras activation, protein tyrosine phospho- 
rylation, and translocation to the particulate fraction of 
signaling molecules that regulate Ras activity. These ob- 
servations uggest hat cAMP negatively regulates TCR- 
mediated signaling systems between the receptor and Ras 
protein. 
2. Materials and methods 
2.1. Materials 
Herbimycin A was kindly provided by Dr. Yoshimasa 
Uehara (National Institutes of Health, Tokyo). 
pMTrasH(Asn-17) [17] was a generous gift from Dr. Geof- 
frey Cooper (Dana-Faber Cancer Institute, MA). hIL-2- 
Luciferase, an expression plasmid containing luciferase 
cDNA as a reporter under the control of human IL-2 
promoter (from the position -541 to +57 of the human 
IL-2 gene) [18], was a generous gift from Dr. Naoko Arai 
(DNAX Research Institute, CA). Anti-CD3 antibodies, 
OKT3 and SPVT3b, were obtained from Drs. Hergen Spits 
and Hans Yssel (DNAX Research Institute, CA). Rabbit 
anti-ZAP-70 antiserum was kindly provided by Dr. Arthur 
Weiss (University of California, San Francisco, CA). Y13- 
259 monoclonal antibody was purified from the culture 
supernatants of the antibody-producing hybridoma by am- 
monium sulfate precipitation. Mouse anti-PLC-yl mono- 
clonal antibody (05-163) was purchased from Upstate Bio- 
technology. Mouse anti-PKC monoclonal antibody (MC5; 
RPN. 536) was from Amersham. Mouse anti-phospho- 
tyrosine monoclonal antibody (PY20; 69-137) was from 
ICN ImmunoBiologicals. CTX and PMA were purchased 
from Calbiochem. PHA was obtained from Sigma. 
Expression vectors, pCMV5-Ras(12V) and pCMV5- 
Ras(17N), were constructed by inserting 0.7 kb EcoRI- 
EcoRI fragment of AL2(Ha)-S22 [19] or 0.8 kb XbaI- 
BamHI fragment of pMTrasH(Asn- 17) [ 17], respectively, 
into cloning restriction sites of pCMV5 [20]. 
2.2. Methods 
Cell culture. The human lymphomic Jurkat cell line was 
cultured in RPMI 1640 supplemented with 10% (v/v) 
fetal calf serum. 
Immunoprecipitation a d immunoblotting. Jurkat cells 
(2 X 107) were washed and suspended in RPMI 1640 
without serum. After incubation for 2.5 h, the cells were 
stimulated with OKT3 (2 /xg/ml), SPVT3b (4 /zg/ml), 
PHA (10 /zg/ml) or PMA (100 ng/ml) for 5 min, col- 
lected by centrifugation, and dissolved into immunoprecip- 
itation buffer (50 mM Hepes-NaOH (pH 7.3), 150 mM 
NaCI, 1% (v/v) Nonidet P-40, 10% (v/v) glycerol, 50 
mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO 4, 
5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 
/zg/ml aprotinin). Lysates were clarified by centrifugation 
and incubated with 5/zg of PY20 and protein A-Sepharose 
(Pharmacia) for 2 h at 4°C. Immunoprecipitates were 
washed five times with 1 ml of immunoprecipitation buffer 
followed by boiling in reducing sodium dodecyl sulfate 
(SDS) gel sample buffer (50 mM Tris-HC1 (pH 6.8), 10% 
(v/v) glycerol, 1% (w/v) SDS, 1% (v/v) 2-mercapto- 
ethanol, 80 /~g/ml bromophenol b ue) for 5 rain. Proteins 
were resolved by SDS-polyacrylamide g l electrophoresis, 
and transferred to a polyvinylidene difluoride membrane 
filter (Immobilon, Millipore). For immunoblotting, mem- 
branes were probed with PY20 (1 /zg/ml), anti-PLC-yl 
antibody (0.5 /xg/ml), anti-PKC antibody (1 /xg/ml) or 
anti-ZAP-70 antibody (1:1000 dilution). Blots were then 
incubated with the second antibody conjugated with 
horseradish peroxidase (Amersham). Immunoreactive 
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bands were visualized by enhanced chemiluminescence 
(Amersham). 
Subcellularfractionation. Jurkat cells were washed and 
suspended in RPMI 1640 without serum. After incubation 
for 2.5 h, the cells were stimulated with SPVT3b (4 
/xg/ml) or PMA (100 ng/ml)  for indicated periods at 
room temperature, collected by centrifugation at 1400 X g 
for 3 rain, suspended in hypotonic buffer (20 mM Hepes- 
NaOH (pH 7.0), 2 mM MgC12, 3 mM EDTA, 2 mM 
EGTA, 1 mM Na3VO 4, 10 /xg/ml aprotinin, 10 /xg/ml 
leupeptin), and disrupted by sonication for 30 s at 4°C. 
Cellular debris were removed by centrifugation at 1400 × g 
for 20 min, and the supernatants were subjected to ultra- 
centrifugation at 100000 X g for 30 rain. The supernatants 
were used as the total soluble fractions (S 100). The pellets 
were dissolved in the hypotonic buffer, sonicated for 15 s 
and centrifuged at 100000 X g for 30 rain. The pellets 
were dispersed into the hypotonic buffer and used as the 
total particulate fractions (P100). The SI00 and P100 
fractions were aliquoted and frozen at -80°C  until use. 
The aliquots of each sample were subjected to SDS-poly- 
acrylamide lectrophoresis and immunoblotting analysis as 
described above. 
Analysis of Ras-bound GDP / GTP state. Jurkat cells 
(2 X 107) were washed with phosphate-free RPMI 1640, 
and the medium was replaced with phosphate-free RPMI 
1640 containing [ 32 P]orthophosphate (14.8 MBq/ml ,  car- 
rier-free; Du Pont-New England Nuclear, NEX-053). After 
incubation for 2.5 h, cells were stimulated with OKT3 (2 
/xg/ml), PHA (10 /xg/ml) or PMA (100 ng/ml)  for 5 
min, and Ras-bound GDP/GTP  was analyzed as follows. 
Cells were collected by centrifugation i  a 1.5-ml plastic 
tube. Thereafter, all procedures were carried out at 0-4°C. 
Six hundred microliters of immunoprecipitation buffer (50 
mM Tris-HC1 (pH 7.5), 20 mM MgC12, 150 mM NaCI, 
0.5% (v /v )  Nonidet P-40, 1 /zg/ml aprotinin) was added 
to the cell pellet. The suspension was gently mixed for 10 
min and was centrifuged at 750 Xg  for 5 min. Two 
hundred microliters of charcoal suspension in immuno- 
precipitation buffer was added to the supernatant. After 
vigorous mixing, the charcoal was removed by centrifuga- 
tion, and the lysate was stored at - 80°C until use. Anti-Ras 
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Fig. 1. Effects of herbimycin A on Ras activation i response tovarious agonists. A: After the treatment with herbimycin A (0.5 /zg/ml) or control solvent 
for 24 h, Jurkat cells were stimulated with OKT3 (2 /xg/ml), PHA (10 /zg/ml), or PMA (100 ng/ml) for 5 min, and Ras-bound GDP/GTP state was 
analyzed. Ras-bound nucleotides were visualized by an image analyzer. B: Jurkat cells were treated with indicated concentrations f herbimycin A for 24 
h, stimulated with control buffer (O), OKT3 (2 /xg/ml, Q), PHA (10 /xg/ml, • ), or PMA (100 ng/ml, • )  for 5 rain, and Ras-bound GDP/GTP state 
was analyzed. 
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monoclonal antibody Y13-259 was mixed with rabbit anti- 
rat IgG antiserum (Cappel Laboratories) and protein A- 
Sepharose CL-4B, and the mixture was incubated at 0°C 
for 1 h. The lysate was added to the antibody protein 
A-Sepharose complex and mixed gently for 2 h. The 
precipitates were washed twice with immunoprecipitation 
buffer and three times with washing buffer (50 mM Tris- 
HC1 (pH 7.5), 20 mM MgC12, 150 mM NaCI), and 
suspended in 20 /zl of elution buffer (20 mM Tris-HCl 
(pH 7.5), 20 mM EDTA, 2% (w/v) SDS, 0.5 mM GDP, 
0.5 mM GTP). The suspension was heated at 65°C for 5 
min and centrifuged. The supernatants were spotted onto a 
polyethyleneimine-cellulose thin-layer chromatography 
plate (J.T. Baker) and developed with 0.75 M KH2PO 4 
(pH 3.4). Total amounts of the radioactivity applied to 
each lane were almost equal in the same chromatography. 
The radioactivity was quantitated with AMBIS radioana- 
lytic system (AMBIS, San Diego, CA). 
Transfection. Jurkat cells were transfected by electropo- 
ration (Gene Pulser; Bio-Rad) as follows: Cells (2 × 107) 
were washed with RPMI 1640, resuspended in 0.8 ml of 
RPMI 1640 containing plasmid DNA samples in Gene 
Pulser cuvettes (165-2088, Bio-Rad). Then, the samples 
were pulsed at 350 V and 960 ~F, mixed with 10 ml of 
the complete RPMI 1640 medium, and transferred to cul- 
ture plates. Time constants were usually 11 ___ 1. At 36 h 
after transfection, various reagents were added and lu- 
ciferase assay was carried out after a further 10 h incuba- 
tion. 
Luciferase assay. Luciferase assay was performed ac- 
cording to the manufacturer's instruction with slight modi- 
fications (Luciferase Assay System El500; Promega). 
Briefly, cells were washed with Hepes-buffered saline (25 
mM Hepes-NaOH (pH 7.05), 140 mM NaC1, 5 mM KC1, 
0.75 mM Na2HPO 4, 6 mM dextrose), lysed within 100/zl 
of lysis buffer (25 mM Tris-phosphate (pH 7.8), 2 mM 
DTT, 2 mM CyDTA, 10% (v/v)  glycerol, 1% (v/v)  
Triton X-100) for 15 min on ice. Cellular debris were 
removed by centrifugation and the aliquots of supernatants 
were assayed for luciferase activity (Lumat LB 9501; 
Berthold). 
3. Results 
3.1. Effects of herbimycin A, a specific inhibitor of  PTKs, 
on Ras activation 
Ras was about 3%. When the cells were stimulated with a 
monoclonal anti-CD3 antibody OKT3 or PHA, accumula- 
tion of the active GTP-bound Ras was observed; approx. 
20% of the total Ras protein was converted to the active 
GTP-bound form within 5 min. PMA, an activator of PKC, 
was a more potent activator of Ras in this system because 
more than 40% of Ras was detected as the GTP-bound 
conformation after PMA treatment. Since PMA has no 
effect on the GDP/GTP state of Ras in other types of 
cells, for example, fibroblasts [21], mast cells [22], and 
B-cells [23], it seems that PMA-induced Ras activation is 
characteristic of T-cells [9] and PCI2 cells [24]. Calcium 
ionophore had no effect on the Ras. GDP/GTP state in 
T-cells [9]. Activation of a family of PTKs is one of the 
earliest events in TCR-mediated signaling systems. The 
TCR complex itself does not possess PTK activity, but 
some of the components of TCR, for instance, ~'-chain, 
have tyrosine residues that are phosphorylated by cellular 
PTKs, and serve as targets of SH2-containing proteins (see 
Refs. [6-8] for reviews). Besides TCR components, other 
signaling proteins are also tyrosine-phosphorylated. From 
the analogy to the signaling systems of growth factors (for 
example, epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF), and insulin) and lymphokines (IL-2, 
IL-3, and granulocyte/macrophage colony-stimulating fac- 
tor (GM-CSF)), non-receptor type PTKs are considered to 
play an important role for activation of Ras following the 
stimulation with OKT3 or PHA in T-cells. On the other 
hand, PMA seems to activate Ras by stimulating PKC 
directly although the precise molecular mechanism of the 
activation is virtually unknown. Therefore, it is important 
to clarify the relationship between TCR-mediated and 
PKC-mediated Ras activation in Jurkat cells. To determine 
whether PTKs are involved in the regulation of Ras activ- 
ity, the effects of herbimycin A, a specific inhibitor of 
PTKs [25,26], on the formation of Ras • GTP were exam- 
ined. When Jurkat cells were exposed to 0.5 /~g/ml 
herbimycin A for 24 h, the formation of Ras. GTP in 
response to OKT3 or PHA was markedly reduced, while 
PMA was still capable of activating Ras (Fig. 1A). The 
inhibitory effect of herbimycin A on the TCR-mediated 
formation of Ras-GTP was dose-dependent; Ras activa- 
tion was completely blocked in cells that had been treated 
with 1 /xg/ml of herbimycin A (Fig. 1B). These results 
suggest hat TCR-induced, but not PMA-induced, signals 
require PTKs for stimulating the formation of the active 
GTP-bound Ras. 
To understand the mechanism of Ras activation in 
TCR-mediated signals, the Ras-bound GDP/GTP state 
was measured in human lymphomic Jurkat cells. Cells 
were metabolically abeled with [32 P]orthophosphate, stim- 
ulated with various agonists and lysed. Ras was immuno- 
precipitated by with Y13-259 antibody, and the Ras-bound 
nucleotides were analyzed by thin-layer chromatography 
(Fig. 1). In the resting cells, the proportion of GTP-bound 
3.2. Effects of  specific inhibition of  PKC on the Ras • GDP 
/ GTP state 
To clarify the role of PKC in TCR- and PTK-mediated 
regulation of Ras, the effects of calphostin C, a specific 
inhibitor of PKC, on Ras activation were examined. 
Calphostin C is permeable to the plasma membrane, and 
blocks the binding of PMA by interacting with the regula- 
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tory domain of PKC [27]. As shown in Fig. 2A, calphostin 
C effectively inhibited not only PMA-induced, but also 
TCR-induced Ras activation in Jurkat cells. Next, we 
examined the effect of down-regulation of PKC on the 
formation of Ras • GTP. Cells were treated with 100 ng/ml 
PMA for 48 h, stimulated with an anti-CD3 antibody, 
PHA, or PMA, and then the Ras-bound GDP/GTP state 
was analyzed. Fig. 2B illustrates that TCR triggering and 
PMA treatment induced about 5- and 10-fold increase of 
Ras - GTP, respectively, in control cells, but when the cells 
were pretreated with PMA, the fold induction of the active 
GTP-bound Ras was approx. 1.5 and 1.2 in response to 
OKT3 and PMA, respectively. These results indicate that 
PKC plays a crucial role in both TCR- and PTK-mediated 
formation of GTP-bound Ras. 
3.3. PLC-TI is ~rosine phospho~lated and translocated 
from the soluble to particulate fractions upon TCR cross- 
linking 
Soluble Particulate 
I I I  I 
SPVT3b PMA SPVT3b PMA 
I - " - - I  I-'1 I ' - - - I  I--I 
Stimulation(min) 0 1 3 5 3 5 0 1 3 5 3 5 
PLC-y1 
PKC 
Fig. 3. Subcellular localization of PLC-71 and PKC during T-cell 
activation. Jurkat cells were stimulated with SPVT3b (4/xg/ml)  or PMA 
(100 ng/ml)  for indicated periods. Cells were disrupted and the total 
soluble and particulate proteins were prepared as described in Section 2. 
PLC-TI and PKC were detected by immunoblotting using specific anti- 
bodies. 
It is known that PLC-yl is activated upon TCR cross- 
linking by tyrosine phosphorylation, and stimulates the 
hydrolysis of inositol phospholipids to produce IP 3 and 
diacylglycerol, which cause mobilization of Ca 2+ and 
activation of PKC, respectively. Since cellular PTKs and 
PKC play important roles in activating Ras upon TCR 
1 








ligation, it is likely that PLC-yl is involved in TCR-medi- 
ated signal transduction to Ras through PKC. We detected 
tyrosine phosphorylation of PLC-yl and its association 
with tyrosine phosphorylated proteins upon TCR stimula- 
tion in Jurkat cells (data not shown, see also Fig. 7C). To 
investigate whether PLC-y I changes its subcellular local- 
ization during T-cell activation, Jurkat cells were stimu- 
lated with an anti-CD3 antibody SPVT3b or PMA, dis- 
rupted by sonication, and fractionated into the soluble and 
particulate fractions. Then, the subcellular localization of 
PLC-yl and PKC were analyzed by immunoblotting (Fig. 
3). In unstimulated cells, PLC-yl and PKC were mostly 
found in the soluble fraction. When cells were stimulated 
with SPVT3b, the amount of PLC-yl in the particulate 
fraction was increased very rapidly. The translocation of 
PLC-yl reached a plateau within 1 min after the stimula- 
tion, and stayed at the same level for at least 5 min. PKC 
in the particulate fraction increased transiently by TCR 
cross-linking. In contrast, stimulation of cells with PMA 
induced the translocation of PKC, but not PLC-71. 
Translocation of PKC upon PMA stimulation sustained at 
least for 5 min, and the amount found in the particulate 
fraction was higher than the case of TCR cross-linking. 
3.4. Ras is ineolved in actiuation of IL-2 promoter in 
Jurkat cells 
Control + PMA 
Fig. 2. Effects of specific inhibition of PKC on Ras activation. A: Effects 
of calphostin C on Ras activation. After the treatment with calphostin C
(10 /xM) or control solvent for 30 min, Jurkat cells were stimulated with 
SPVT3b (4 /~g/ml) or PMA (100 ng/ml)  for 5 min, and Ras-bound 
GDP/GTP state was analyzed. B: Effects of downregulation f PKC on 
Ras activation. After the treatment with PMA (100 ng/ml)  or control 
solvent for 48 h, Jurkat cells were stimulated with OKT3 (2 /xg/ml), 
PHA (10 /zg/ml), or PMA (100 ng/ml)  for 5 min, and Ras-bound 
GDP/GTP state was analyzed. 
To elucidate whether the activation of Ras is required 
for the stimulation of IL-2 gene expression, we examined 
the effects of dominant-positive (G12V) and dominant- 
negative (S 17N) mutants of Ras. Expression vectors con- 
taining the mutant ras cDNAs under the control of a 
cytomegalovirus (CMV) promoter were constructed 
(termed pCMV5-Ras(12V) and pCMV5-Ras(17N), respec- 
tively), and introduced into Jurkat cells with a reporter 
plasmid (hlL-2-Luciferase). As shown in Fig. 4A, A23187, 
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Fig. 4. Effects of activated (GI2V) and dominant-inhibitory (S17N) Ras 
proteins on the induction of human IL-2 promoter. A: Enhancement of
the induction of human IL-2 promoter by activated Ras(GI2V). Jurkat 
cells were transfected with hlL-2-Luciferase (2•5 /xg) and pCMV5- 
Ras(12V) (2.5 /.tg). 36 h post-transfection, cells were stimulated with 
A23187 (5 ~M), PHA (10/zg/ml), PMA (20 ng/ml), or their combina- 
tion for 10 h. Then, the cells were harvested and luciferase activity was 
measured. B: Blockade of PMA plus A23187-induced activation of IL-2 
promoter by dominant-inhibitory Ras(S 17N). Jurkat cells were transfected 
with hIL-2-Luciferase (5 /zg) and various amounts of pCMV5-Ras(17N). 
36 h post-transfection, cells were stimulated with PMA (20 ng/ml) plus 
A23187 (5 /zM) for 10 h. Then, the cells were harvested and luciferase 
activity was measured. 
PHA, or PMA alone gave only a very weak induction of 
IL-2 promoter, while PMA in combination with A23187 or 
PHA remarkably stimulated the promoter. Expression of 
the constitutively active Ras alone gave no significant 
activation of hlL-2-Luciferase, indicating that the activa- 
tion of Ras pathway by itself is insufficient for the induc- 
tion of IL-2 promoter. The result is in accordance with the 
observation that PHA or PMA alone was unable to stimu- 
late the promoter sufficiently although both of them can 
induce Ras activation. A 1.5- to 2-fold enhancement of the 
luciferase activity by Ras(G12V) was detected in cells 
stimulated by various agonists or their combination, sug- 
gesting that the Ras pathway plays an important role for 
induction of IL-2 promoter when other essential pathways 
are activated. Then, we examined the effect of the domi- 
nant-inhibitory Ras(S17N). When Jurkat cells were co- 
transfected with hlL-2-Luciferase and various amounts of 
pCMV5-Ras(17N), the PMA plus A23187-induced activa- 
tion of the reporter plasmid was diminished in a dose-de- 
pendent manner (Fig, 4B). These results indicate that 
activation of Ras is essential, but not sufficient, for the 
stimulation of IL-2 promoter. 
3.5. CTX inhibits activation of lL-2 promoter 
In TCR-mediated signaling systems, cAMP-elevating 
agents, for example, forskolin, CTX, and prostaglandin 
(PG) E 2, are known to inhibit IP 3 production, accumula- 
tion of cytoplasmic free calcium and IL-2 production. To 
understand the role of cAMP in Ras-mediated signal trans- 
duction in T-cells, we first tested the effects of cAMP- 
elevating agents on the activation of IL-2 promoter. CTX, 
a pathogenic exotoxin of Vibrio cholerae, ADP-ribosylates 
G~ a protein, and makes G~ ~ constitutively active. Jurkat 






• ~1 + CTX (1 ng/ml) 
D + CTX (100 .g/ml) 
0 __  L 
Control A23187 PHA PMA PHA+ PHA+ PMA+ 










~¢2000 D+ CAMp 3O 
~, 20 
~ 1111111 10 
~ o 
tco-ro,. ,- . . . . . .  ii ii i 
A23187 PMA A23187 
Fig. 5. Effects of cAMP-elevating a ents on the induction of human IL-2 
promoter. A: Inhibition of IL-2 promoter stimulation in response to 
various agonists by CTX. Jurkat cells were transfected with hlL-2- 
Luciferase (2.5 /~g). 30 h post-transfection, i dicated concentrations of
CTX were added, and the cells were incubated for 5 h. Then, the cells 
were stimulated with A23187 (5 /xM), PHA (10 /zg/ml), PMA (20 
ng/ml), or their combination for 10 h, harvested, and luciferase activity 
was measured. B: Inhibition of PMA plus A23187-induced activation of 
IL-2 promoter by activated Q a(Q213L). Jurkat cells were transfected 
with hlL-2-Luciferase (5 /xg) and various amounts of pCMVG~QL. 36 h 
post-transfection, cells were stimulated with PMA (20 ng/ml) plus 
A23187 (5 /zM) for 10 h. Then, the cells were harvested and luciferase 
activity was measured• C: Inhibition of IL-2 promoter stimulation in 
response to various agonists by dBcAMP. Jurkat cells were transfected 
with hlL-2-Luciferase (2.5 /xg). 30 h post-transfection, dBcAMP (1 mM) 
was added, and the cells were incubated for 5 h. Then, the cells were 
stimulated with A23187 (5 /xM), PHA (10/xg/ml), PMA (20 ng/ml), or 
their combination for 10 h, harvested, and luciferase activity was mea- 
sured. 
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with CTX prior to the stimulation. As shown in Fig. 5A, 
transcription of hIL-2-Luciferase in response to PMA plus 
A23187 or PMA plus PHA was lowered in CTX-treated 
cells. We next examined the effect of a dominant-active 
G~a protein (Q213L) [28] to confirm that the action of 
CTX is mediated by G~ o~ protein. Fig. 5B shows dose-de- 
pendent decrease of the luciferase activity by co-transfec- 
tion of pCMVG~QL, a plasmid that expresses G~ ce (Q213L) 
under the control of CMV promoter. Moreover, we tested 
the effect of dBcAMP, an analog of cAMP, which is 
permeable to the plasma membrane, and stable within the 
cell. When Jurkat cells were treated with dBcAMP prior to 
the addition of various agonists, activation of IL-2 reporter 
gene was markedly inhibited (Fig. 5C). These results 
suggest that CTX inhibits IL-2 gene expression by activat- 
ing G~ c~ protein, which causes the increase of cytoplasmic 
cAMP concentration. 
3.6. CTX inhibits Ras actiL'ation in response to TCR 
triggering but not PMA treatment 
Since Ras is essential for the stimulation of IL-2 pro- 
moter by TCR-mediated signals, we examined the effect of 
CTX on Ras activation in response to TCR cross-linking 
and PMA treatment. When Jurkat cells were treated with 
CTX prior to various stimuli, TCR-mediated formation of 
the active GTP-bound Ras was much reduced, while 
PMA-induced Ras activation was not affected (Fig. 6A). 
We also examined the effect of dBcAMP on Ras activa- 
tion. Similarly to the effect of CTX, an anti-CD3 
antibody-induced but not PMA-induced formation of Ras - 
GTP was inhibited in cells pretreated with dBcAMP (Fig. 
6B). 
3.7. CTX inhibits tyrosine phosphorylation of cellular sub- 
strates 
In TCR signaling, the major proportion of the signals 
that induce the formation of Ras. GTP is mediated by 
PKC. Since PMA-induced formation of Ras • GTP was not 
inhibited by CTX, it is likely that one of the target sites of 
CTX in TCR-mediated signals exists between TCR and 
PKC. Thus, we analyzed the effect of CTX on the induc- 
tion of tyrosine phosphorylation f cellular proteins, which 
is thought to be important for TCR-induced, but not 
PMA-induced Ras activation. When the cells were pre- 
treated with CTX, tyrosine phosphorylation of various 
cellular proteins was severely impaired (Fig. 7A). Using 
specific antibodies, we tested the effect of CTX on tyro- 
sine phosphorylation of ZAP-70 and PLC-yl, which are 
implicated in TCR-induced Ras activation. ZAP-70 was 
originally identified as a tyrosine phosphorylated protein 
that was associated with the ~'-chain of the TCR, and was 
activated by tyrosine phosphorylation. It has recently been 
reported that mutations in both alleles of the ZAP-70 gene 
result in severe combined immunodeficiency disease 
(SCID) in human, suggesting a key role of ZAP-70 in TCR 
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Fig. 6. Inhibition of Ras. GTP formation upon various stimuli by cAMP- 
elevating agents. A: CTX inhibits anti-CD3- or PHA-induced, but not 
PMA-induced increase of Ras-GTP. Jurkat cells were treated with CTX 
(2 /zg/ml) or control buffer for 3 h, stimulated with OKT3 (2 p~g/ml), 
PHA (10 /xg/ml), or PMA (100 ng/ml)  for 5 min, and Ras-bound 
GDP/GTP state was analyzed. Ras-bound nucleotides were visualized by 
an image analyzer. B: dBcAMP inhibits anti-CD3-induced, but not 
PMA-induced increase of Ras-GTP. Jurkat cells were treated with dB- 
cAMP (1 mM) or control buffer for 5 h, stimulated with SPVT3b (4 
/xg/ml) or PMA (100 ng/ml)  for 5 min, and Ras-bound GDP/GTP state 
was analyzed. 
signaling systems [29-31]. PLC-yl is activated through 
tyrosine phosphorylation i  response to the TCR signals. 
In addition, it has been reported that forskolin, which 
activates adenylyl cyclase directly, prevents tyrosine phos- 
phorylation and activation of PLC-TI in Jurkat cells 
[32,33]. Following TCR stimulation, ZAP-70 and PLC-yl 
were found in the immunoprecipitates of anti-phospho- 
tyrosine antibody when the cells were stimulated with 
TCR agonists, but not with PMA. When cells were treated 
with CTX prior to the stimulation, neither ZAP-70 nor 
PLC-T1 was detected in the anti-phosphotyrosine 
immunoprecipitates (Fig. 7B and C). These results suggest 
that CTX presumably interferes with the action of cellular 
tyrosine kinases to signal transducing proteins, such as 
ZAP-70 and PLC-y 1. 
3.8. CTX inhibits translocation of ZAP-70, PLC-yl, and 
PKC from the soluble to particulate fraction by TCR-medi- 
ated signals 
Next, we analyzed the change of subcellular localiza- 
tion of ZAP-70, PLC-yl and PKC in response to SPVT3b 
230 T. Ohtsuka et al. / Biochimica et Biophysica Acta 1310 (1996) 223-232 
and PMA in CTX-treated and non-treated Jurkat cells. The 
cells were stimulated with SPVT3b or PMA and sonicated, 
and then proteins were fractionated into the soluble and 
particulate fractions by centrifugation and analyzed by 
immunoblotting as described in Section 2. Fig. 8 shows 
that, in unstimulated cells, ZAP-70 and PLC-yl were 
mostly found in the soluble fraction, whereas, in cells 
stimulated with SPVT3b, the amounts of ZAP-70 and 
PLC-yl in the particulate fraction increased very rapidly. 
The amounts of ZAP-70 and PLC-'y1 found in the particu- 
late fraction reached a plateau within 1 min, and stayed at 
the same level at least for 5 min. PKC detected in particu- 
late fraction increased transiently by TCR cross-linking; its 
amount returned to the initial level after 3 min stimulation. 
Stimulation of cells with PMA induced the translocation of
PKC very effectively, but did not affect the localization of 
ZAP-70 or PLC-yl.  When the cells were pretreated with 
CTX, the translocation of ZAP-70, PLC-y 1 and PKC after 
TCR-stimulation significantly diminished, while PMA was 
still able to stimulate the translocation of PKC to the 
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Fig. 8. Inhibition of translocation of cellular signaling molecules by CTX. 
Jurkat cells were treated with CTX (2 /xg/ml) or control buffer for 4 h, 
and stimulated with SPVT3b (4 /xg/ml) or PMA (100 ng/ml) for 
indicated periods. Cells were disrupted and the total soluble and particu- 
late proteins were prepared as described in Section 2. Proteins were 
subjected to immunoblot analysis using anti-ZAP-70, anti-PLC-3,1, or 
anti-PKC antibodies. 
hibits TCR-mediated protein interactions that induce 
translocation of these signaling molecules from the soluble 
to particulate fractions. 
4. Discussion 
B control OKT3 PMA 
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Fig. 7. Inhibition of tyrosine phosphorylation f cellular proteins by CTX. 
Jurkat cells were treated with CTX (2 /~g/ml) or control buffer for 3 h, 
and stimulated with OKT3 (2 /xg/ml), PHA (10 /xg/ml), or PMA (100 
ng/ml) for 5 min. Phosphotyrosine containing proteins were immuno- 
precipitated with anti-phosphotyrosine a tibody, PY20, and subjected to 
immunoblot analysis using anti-phosphotyrosine (A), anti-ZAP-70 (B), or 
anti-PLC-71 (C) antibodies. 
In this paper, we studied Ras-mediated signal transduc- 
tion for T-cell activation. From the experiments using 
specific inhibitors for tyrosine kinases and PKC, it was 
suggested that PKC plays a crucial role in Ras activation 
following TCR and tyrosine kinase-mediated stimulation 
in Jurkat cells (Figs. 1 and 2). Since alteration of the 
subcellular localization of PLC-T1 and PKC from soluble 
to particulate fractions in response to TCR stimulation was 
observed, it is possible that TCR-triggered signals are 
transmitted through PLC-yl and PKC to activate Ras 
protein. Furthermore, both the increase in Ras • GTP (data 
not shown) and the translocation of PLC-yl and PKC 
(Fig. 3) were transient, suggesting the presence of a feed- 
back mechanism. Izquierdo et al. [34] reported that PKC 
was dispensable for TCR-mediated Ras activation based 
on the observation that neither a pseudosubstrate inhibitor 
for PKC nor deprivation of calcium prevented Ras - GTP 
formation in permeabilized T-lymphoblasts. Reasons for 
the discrepancy between their results and ours are not clear 
at present, but it may be due to the difference between 
peripheral T-lymphocytes and Jurkat cell line. 
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Tyrosine kinase receptors (e.g., EGF, PDGF, and in- 
sulin receptors) activate Ras through interaction between 
adaptors (e.g., Shc and Grb-2), and Ras-guanine nucleotide 
exchange proteins (e.g., mSos) [4]. Recently, Ravichandran 
et al. [35] reported the specific interaction among TCR 
chain, Shc, Grb-2, and mSos, suggesting the implication of 
these molecules in the modulation of Ras activity in 
response to TCR stimulation. In addition, several tyrosine 
phosphorylated proteins, for example, p. 36-38 [36,37], p. 
75 [38], p. 116 [39], and p. 150 [36] were associated with 
adaptor proteins, although the function of these molecules 
remains unclear. On the other hand, another proto-onco- 
gene product, Vav, which is expressed specifically in 
bematopoietic cells, has been reported to be involved in 
Ras activation in T-cells [40]. Gulbins et al. [41] reported 
that Vav was directly activated by phorbol esters and 
diglycerides, and then it enhanced GDP/GTP exchange of 
Ras. Furthermore, there is a report showing the association 
of Vav and ZAP-70 [42]. Collectively, multiple routes 
linking TCR and Ras seem to exist in T-lymphocytes, and 
the usage of these pathways may differ among different 
T-cell lines. Proliferation signals in T-cells induced by 
IL-2 stimulation also involves Ras activation [22], in which 
Shc, Grb-2, and Sos act as upstream regulators of Ras 
[43,44]. 
We showed that activated Ras(G12V), in combination 
with other signals including TCR cross-linking with anti- 
CD3 antibody or PHA and treatment with A23187 or 
PMA, enhanced expression of IL-2 promoter, although 
Ras(GI2V) alone was not able to stimulate the IL-2 pro- 
moter (Fig. 4). The results suggest important roles of 
TCR-triggered, but Ras-independent signal transduction 
pathways because the stimulation with PHA or PMA alone 
is sufficient for the induction of Ras activation. On the 
contrary, it has been observed that, in EL-4 mouse T-cells, 
the activated Ras could replace the signal mediated by 
PKC; it almost fully stimulated the transcription of IL-2 
promoter and AP-I or NF-•B binding sequences when 
calcium ionophore, A23187 or ionomycin, were added 
[45,46]. As shown in the present study, a dominant in- 
hibitory Ras (S17N) blocked PMA plus A23187-induced 
stimulation of IL-2 promoter, indicating that Ras-mediated 
signaling pathway is essential for IL-2 promoter stimula- 
tion. The results are similar to the observation by Rayter et 
al. [45], but different from the results by Baldari et al. [47], 
which showed the suppression of the effect of Ras(S17N) 
by PMA. Collectively, we propose the important roles of 
Ras-dependent as well as Ras-independent pathways for 
the stimulation of IL-2 promoter, although we should 
carefully interpret the data from experiments using domi- 
nant-active and dominant-negative mutants of Ras because 
it is not fully clarified which of the transcriptional regula- 
tory elements are responsible for Ras-mediated activation 
signaling, and thus we cannot completely exclude sec- 
ondary effects of the mutants. In addition, a dominant- 
negative mutant of Raf-l, a serine/threonine kinase that 
specifically interacts with, and is regulated by, Ras, also 
inhibits PMA plus PHA-induced transcription of IL-2 pro- 
moter [48], implying that Ras pathway is essential for 
T-cell activation. 
Pretreatment with CTX resulted in reduced stimulation 
of IL-2 promoter as shown in Fig. 5A. Since an activated 
mutant G~ a(Q213L) and dBcAMP were capable of substi- 
tuting for CTX (Fig. 5B and C), it is likely that increase of 
the intracellular concentrations of cAMP negatively modu- 
lates the T-cell activation. Both CTX and dBcAMP dimin- 
ished Ras - GTP increase in response to TCR stimulation, 
but not by PMA treatment, suggesting that signal transduc- 
ing molecules between the receptor and PKC are nega- 
tively regulated by cAMP (Fig. 6). While the PMA-promo- 
ted Ras • GTP formation was not affected by cAMP elevat- 
ing reagents, they blocked almost completely PMA plus 
PHA- or PMA plus A23187-induced IL-2 promoter acti- 
vation (Fig. 5). The results indicate that not only Ras-de- 
pendent (as described above), but also Ras-independent 
signals triggered by TCR cross-linking are critical for the 
induction of IL-2 promoter, which is consistent with the 
result that an activated Ras(G12V) alone is insufficient for 
IL-2 promoter stimulation. As addressed above, tyrosine 
kinases, PLC-yl, and PKC seem to play important roles 
for Ras activation in Jurkat cells. Hence, we next exam- 
ined whether these molecules were modulated by cAMP 
elevating reagents, and found that tyrosine phosphorylation 
of cellular proteins of various molecular weights, espe- 
cially, ZAP-70 and PLC-yl was abolished with CTX 
treatment prior to the stimulation (Fig. 7). Moreover, 
anti-CD3 antibody-induced translocation f these molecules 
to particulate fraction was diminished almost completely 
after CTX-treatment as shown in Fig. 8. Hence, the activ- 
ity of tyrosine kinases stimulated by TCR seems to be 
suppressed by cAMP/protein kinase A (PKA) system 
although it is not clear at present which of the already 
known TCR-related tyrosine kinases, Fyn, Lck, and ZAP- 
70, or others are mainly targeted. 
In various types of cells, including fibroblast cell lines 
[49-52], aortic smooth muscle cells [53], and adipocytes 
[54], cAMP/PKA signals antagonized Ras/mitogen- 
activated protein kinase (MAPK) pathway. In the case of 
Rat-1 cells, cAMP appeared to prevent Ras/Raf interac- 
tion or mSos phosphorylation, whereas tyrosine kinase 
activities and Ras. GTP formation were unaffected [49- 
51]. Therefore, a unique mechanism for Ras regulation 
through cAMP signal seems to function in T-cells. 
In addition to the TCR signaling, co-stimulatory signals 
derived from antigen-presenting cells are required for max- 
imal induction of the IL-2 production and growth promo- 
tion in T-cells [55]. The second signals are mediated by the 
interaction of CD28 and CTLA-4 receptors on the surface 
of T-cells with B7-1 and B7-2 molecules. Although the 
precise mechanism for the augmentation of T-cell activa- 
tion by CD28 signaling remains unclear, the pathway is 
thought to be relatively independent of antigen-specific 
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TCR-mediated signaling cascades. It may be important to 
investigate whether tyrosine kinase, PKC, and Ras-media- 
ted pathways are modulated by the co-stimulation of T- 
cells. 
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